Clinical trials in Toulon – page 76

1 537 clinical trials in Toulon, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Toulon at a glance

1 537

clinical trials

Research sites1

Quick filters

1 537 trials in Toulon

Open in trial search

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Dabrafenib Mesylate
Sponsor:Novartis Pharma AG

Contact Research Centre

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bemarituzumab
Sponsor:Amgen Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:AstraZeneca AB

Contact Research Centre

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Novartis Pharma AG

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Novartis Pharma AG

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Severe myoclonic epilepsy of infancy

Not recruiting

Study of zorevunersen to reduce seizures in patients with Dravet syndrome

InvestigationalNo placebo

Study of zorevunersen to reduce seizures in patients with Dravet syndrome

InvestigationalNo placebo

France

Participants:0–17 years
Substances:Zorevunersen sodium
Sponsor:Stoke Therapeutics Inc.

Contact Research Centre

Gastric cancer

Not recruiting

Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo

Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Domvanalimab
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:S095035
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Toulon

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer treatments, including innovative combination therapies and immunotherapy approaches. Multiple studies evaluating novel drug combinations to improve patient outcomes.

Advanced NSCLC Treatments
Immunotherapy Combinations
Post-Surgery Therapies

Research spans various disease stages and includes both early-stage and metastatic cancer treatments.

02 Hematology & Blood Disorders

Studies investigating treatments for chronic lymphocytic leukemia and blood-related conditions. Research includes evaluation of novel drug combinations and targeted therapies.

Leukemia Treatments
Blood Cancer Therapies
Lymphoma Management

Focus on improving treatment outcomes for previously untreated patients with coexisting conditions.

03 Cardiovascular Research

Investigations into stroke prevention and treatment of thrombotic conditions. Studies evaluating new anticoagulants and therapeutic approaches for various cardiovascular conditions.

Thrombosis Management
Heart Failure Treatments
Stroke Prevention Strategies

Clinical trials examining innovative treatments for atrial fibrillation and deep vein thrombosis.

Back to France All countries